Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference 2025
27 slides from Jazz Pharmaceuticals's conference presentation, Jan 13, 2025
Slide 1: Innovating to Transform the Lives of Patients and Their Families
Exhibit 99.1 January 2025 rd 43 Annual J.P. Morgan Healthcare Conference Innovating to Transform the Lives of Patients and Their Families Markella ® EPIDIOLEX patient diagnosed with Dravet syndrome January 2025
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Who We Are
Our Purpose is to innovate to transform the lives of patients and their families. Who We Are We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully. Jennie Caroline Xywav patient liv
Slide 4: Positioned to Drive Long-term Shareholder Value
Positioned to Drive Long-term Shareholder Value PIPELINE Zanidatamab and Zepzelca indication expansion COMMERCIAL opportunities; additional Growth and diversified pipeline programs under revenues expected to generate development Operational significant cash flow excellence and a disciplined, strateg
Slide 5: Growing and Diversified Commercial Portfolio
Growing and Diversified Commercial Portfolio 1 2018 Revenue 2021 Revenue 2024 Guidance $1.9 billion $3.1 billion $4.0 - $4.1 billion 74% 41% 11% 2 Launched / of revenues driven of revenues driven of revenues driven by Xyrem in 2018 by Xyrem in 2021 by Xyrem and AG Acquired royalties in 3Q24 Xyrem &
Slide 6: Strategic Transactions Driving Growth and Expanding Capabilities
Strategic Transactions Driving Growth and Expanding Capabilities WELL-POSITIONED FOR ZEPZELCA GW ACQUISITION ZANIDATAMAB CORPORATE DEVELOPMENT Rapidly Accretive Transaction Transformational Transaction Broad Oncology Development Transaction FINANCIAL STRENGTH • $2.6B in cash, cash equivalents and 3
Slide 7: Track Record of Successfully Growing and Diversifying Commercial Portfolio
Track Record of Successfully Growing and Diversifying Commercial Portfolio Expect to meet 2024 total, neuroscience and $4.0B- $4.1B 1 $3.8B oncology revenue guidance $3.7B $3.1B 20 Consecutive Years $2.4B $2.2B $1.9B YoY Revenue Growth 2005 – 2024G 13.5% Total Revenue CAGR 2 2018 – 2024G midpoint 20
Slide 8: Pipeline: Focused Investments in Promising R&D Portfolio
Pipeline Focused Investments in Promising R&D Portfolio January 2025 8
Slide 9: Key Pipeline Programs
Key Pipeline Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY NEAR-TERM CATALYSTS Key Clinical Programs ® 2L BTC (pivotal) Ziihera approved in 2L BTC in 4Q24 Phase 3 1L GEA (pivotal) Phase 3 top-line PFS readout estimated 2Q25 Phase 3 1L BTC Phase 3 confirmatory trial in 1L BTC ongoing Zanidata
Slide 10: Zanidatamab Has the Potential to Transform HER2-Targeted Therapies
Zanidatamab Has the Potential to Transform HER2-Targeted Therapies Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb with compelling and durable survival data Best-in-Class $2B+ Novel and Compelling Profile Commercial Differentiated Clinical Data in Addresses Opportunity MO
Slide 11: Rapidly Advancing Zanidatamab Development Program
Rapidly Advancing Zanidatamab Development Program 2024 2025 2026 and Beyond BTC BTC BTC • Expect to complete 1L confirmatory ✓ Ziihera approved in 2L BTC in 4Q24• Potential EU approval as early trial as 2Q25 ✓ Initiated 1L confirmatory trial GEA GEA ✓ 2L BTC MAA validated by EMA • Potential 1L appro
Slide 12: Zepzelca: Positive Top-Line Results from 1L ES-SCLC Phase 3 Trial
Zepzelca: Positive Top-Line Results from 1L ES-SCLC Phase 3 Trial 1 SCLC U.S. Patients IMforte Phase 3 Trial: 30K • Demonstrated statistically significant and clinically meaningful 27K improvement in OS and PFS primary endpoints for 1L ES-SCLC 9K • Potential to delay disease progression and extend s
Slide 13: Key Commercial Products: Highly Differentiated Therapies Poised for Growth
Key Commercial Products Highly Differentiated Therapies Poised for Growth January 2025 13
Slide 14: Highly Differentiated Medicines for Patients with Serious Diseases
Highly Differentiated Medicines for Patients with Serious Diseases 1 Top-line growth driven by diversified businesses spanning Sleep, Epilepsy and Oncology, each annualizing >$1B Oncology Neuroscience Potential to be the #1 treatment Standard of care in #1 branded treatment #1 branded treatment ther
Slide 15: Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes
Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes Compelling and Favorable Combination data Unique dual-targeting durable responses tolerability profile supports ability to HER2 bispecific help drive improved contributes to combine with other antibody provides patient outco
Slide 16: BTC Launch: Building Momentum for Multiple Indications
BTC Launch: Building Momentum for Multiple Indications Ziihera Clinical Data 51.6% 14.9m 2.5% Overall Median Duration Discontinuation 1 1 1 Response Rate of Response Rate Mark Ziihera patient living with Biliary Tract Cancer Establish Ziihera as the standard Build momentum for Ziihera’s potential as
Slide 17: BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure
BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure • Proven team with deep oncology experience, including extensive expertise in the HER2 therapy Right Team, space will help drive additional adoption and uptake Right Capabilities • Infrastructure in place for a successful Ziihera laun
Slide 18: Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential
Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential Significant regulatory progress: • Ziihera now approved in the U.S. for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC3+) BTC Other HER2-Expressing • EMA validated MAA; potential approval as
Slide 19: Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm
Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm Well-established as 2L SCLC treatment of choice 1 • >$1.1 billion in revenue since launch in mid-2020 Plan to submit sNDA for 1L ES-SCLC in 1H25 • Reported statistically significant and clinically meaningful OS and PFS ® results from the P
Slide 20: Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols
Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols Sustained asparaginase activity over the course of therapy essential to 1 treatment success of ALL/LBL patients 2 • ~$1.1 billion in revenue since launch in mid-2021 • Only therapy available to patients in the U.S. who have a hyp
Slide 21: Epidiolex: Durable Growth; High Unmet Need in Pediatric Onset Epilepsy
Epidiolex: Durable Growth; High Unmet Need in Pediatric Onset Epilepsy Broad spectrum efficacy through novel mechanism of action • Poised to reach blockbuster status in 2025 • Continued education on synergies from treatment in combination with clobazam 1 • Further data generation, including beyond-s
Slide 22: Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity
Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity 1 • Annualizing over $1.5 billion as of 3Q24 • Xywav remains #1 branded treatment for narcolepsy • Xywav is the only approved oxybate therapy that doesn’t carry a warning and precaution related to high sodium intake • FDA published
Slide 23: Well-Positioned to Deliver Long-Term Value
Well-Positioned to Deliver Long-Term Value Operational Excellence and Commercial Execution January 2025 23
Slide 24: Delivering Significant Value Through Strategic Capital Allocation
Delivering Significant Value Through Strategic Capital Allocation DISCIPLINED CAPITAL STRONG FINANCIAL STRATEGIC PRIORITIES DEPLOYMENT POSITION $ COMMERCIAL GROWTH Diversified and growing ~ 1.0B New indications revenue base 1 Cash from operations Geographic expansion PIPELINE EXPANSION $ 2.6B Differ
Slide 25: Well-Positioned to Deliver Meaningful Shareholder Value
Well-Positioned to Deliver Meaningful Shareholder Value COMMERCIAL EXECUTION PIPELINE CATALYSTS Executing launch in 2L BTC Zanidatamab Phase 3 1L GEA top-line data: estimated 2Q25 Reaching blockbuster status Potential EU 2L BTC approval as early as 2Q25 Operational excellence and a disciplined, stra
Slide 26: Q&A
Q&A January 2025 26
Slide 27: Thank You
Thank You o~ Pharmaceuticals.
Jazz Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix